Literature DB >> 19802016

Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein.

M R Abedini1, E J Muller, R Bergeron, D A Gray, B K Tsang.   

Abstract

Although Akt is a determinant of cisplatin (cis-diaminedichloroplatinum (CDDP)) resistance in ovarian cancer cells, which is related in part to its inhibitory action on p53 activation, precisely how Akt confers CDDP resistance is unclear. In this study, we show that CDDP induced p53-dependent Fas-associated death domain-like interleukin-1beta-converting enzyme (FLICE)-like inhibitory protein (FLIP) degradation in chemosensitive ovarian cancer cells but not their resistant counterparts. CDDP induced FLIP-p53-Itch interaction, colocalization and FLIP ubiquitination in chemosensitive but not chemoresistant ovarian cancer cells. Moreover, although activated Akt inhibited CDDP-induced FLIP degradation and apoptosis in sensitive cells, these responses were facilitated by dominant-negative Akt expression in chemoresistant cells. Inhibition of Akt function also facilitated p53-FLIP interaction and FLIP ubiquitination, which were attenuated by p53 silencing. These results suggest that Akt confers resistance, in part, by modulating CDDP-induced, p53-dependent FLIP ubiquitination. Understanding the precise etiology of chemoresistance may improve treatment for ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19802016     DOI: 10.1038/onc.2009.300

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  62 in total

1.  Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance.

Authors:  Kazuhiro Tanaka; Ivan Babic; David Nathanson; David Akhavan; Deliang Guo; Beatrice Gini; Julie Dang; Shaojun Zhu; Huijun Yang; Jason De Jesus; Ali Nael Amzajerdi; Yinan Zhang; Christian C Dibble; Hancai Dan; Amanda Rinkenbaugh; William H Yong; Harry V Vinters; Joseph F Gera; Webster K Cavenee; Timothy F Cloughesy; Brendan D Manning; Albert S Baldwin; Paul S Mischel
Journal:  Cancer Discov       Date:  2011-09-13       Impact factor: 39.397

2.  Alterations in nuclear pore architecture allow cancer cell entry into or exit from drug-resistant dormancy.

Authors:  Yayoi Kinoshita; Tamara Kalir; Jamal Rahaman; Peter Dottino; D Stave Kohtz
Journal:  Am J Pathol       Date:  2011-11-07       Impact factor: 4.307

3.  Ubiquitin E3 ligase CRL4(CDT2/DCAF2) as a potential chemotherapeutic target for ovarian surface epithelial cancer.

Authors:  Wei-Wei Pan; Jian-Jie Zhou; Chao Yu; Ying Xu; Lian-Jun Guo; Hai-Yi Zhang; Dawang Zhou; Fang-Zhou Song; Heng-Yu Fan
Journal:  J Biol Chem       Date:  2013-08-30       Impact factor: 5.157

Review 4.  Chemoresistance and targeting of growth factors/cytokines signalling pathways: towards the development of effective therapeutic strategy for endometrial cancer.

Authors:  Fengjun Guo; Haina Zhang; Zanhui Jia; Manhua Cui; Jingyan Tian
Journal:  Am J Cancer Res       Date:  2018-07-01       Impact factor: 6.166

5.  The combination of thioxodihydroquinazolinones and platinum drugs reverses platinum resistance in tumor cells by inducing mitochondrial apoptosis independent of Bax and Bak.

Authors:  Wei Qian; Joseph Salamoun; Jingnan Wang; Vera Roginskaya; Bennett Van Houten; Peter Wipf
Journal:  Bioorg Med Chem Lett       Date:  2014-12-30       Impact factor: 2.823

6.  The IGF-1R/AKT pathway has opposing effects on Nutlin-3a-induced apoptosis.

Authors:  Batzaya Davaadelger; Ricardo E Perez; Yalu Zhou; Lei Duan; Steven Gitelis; Carl G Maki
Journal:  Cancer Biol Ther       Date:  2017-07-11       Impact factor: 4.742

7.  Molecular imaging reveals a role for AKT in resistance to cisplatin for ovarian endometrioid adenocarcinoma.

Authors:  Hanxiao Wang; Stefanie Galbán; Rong Wu; Brittany M Bowman; Amanda Witte; Katrin Vetter; Craig J Galbán; Brian D Ross; Kathleen R Cho; Alnawaz Rehemtulla
Journal:  Clin Cancer Res       Date:  2012-10-24       Impact factor: 12.531

8.  Death domain-associated protein DAXX promotes ovarian cancer development and chemoresistance.

Authors:  Wei-Wei Pan; Jian-Jie Zhou; Xiao-Man Liu; Ying Xu; Lian-Jun Guo; Chao Yu; Qing-Hua Shi; Heng-Yu Fan
Journal:  J Biol Chem       Date:  2013-03-28       Impact factor: 5.157

9.  Cellular responses to Cisplatin-induced DNA damage.

Authors:  Alakananda Basu; Soumya Krishnamurthy
Journal:  J Nucleic Acids       Date:  2010-08-08

10.  AKT inhibition mitigates GRP78 (glucose-regulated protein) expression and contribution to chemoresistance in endometrial cancers.

Authors:  Michael J Gray; Paulette Mhawech-Fauceglia; Eunjeong Yoo; Wangrong Yang; Eijean Wu; Amy S Lee; Yvonne G Lin
Journal:  Int J Cancer       Date:  2013-02-08       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.